| Autor: |
Schneider Y; Dr Schneider, Dr Saumoy, and Dr Cohen-Mekelburg are clinical fellows; Dr Steinlauf is an assistant professor of medicine; and Dr Scherl is a professor of clinical medicine in the Division of Gastroenterology and Hepatology at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York., Saumoy M; Dr Schneider, Dr Saumoy, and Dr Cohen-Mekelburg are clinical fellows; Dr Steinlauf is an assistant professor of medicine; and Dr Scherl is a professor of clinical medicine in the Division of Gastroenterology and Hepatology at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York., Cohen-Mekelburg S; Dr Schneider, Dr Saumoy, and Dr Cohen-Mekelburg are clinical fellows; Dr Steinlauf is an assistant professor of medicine; and Dr Scherl is a professor of clinical medicine in the Division of Gastroenterology and Hepatology at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York., Steinlauf AF; Dr Schneider, Dr Saumoy, and Dr Cohen-Mekelburg are clinical fellows; Dr Steinlauf is an assistant professor of medicine; and Dr Scherl is a professor of clinical medicine in the Division of Gastroenterology and Hepatology at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York., Scherl EJ; Dr Schneider, Dr Saumoy, and Dr Cohen-Mekelburg are clinical fellows; Dr Steinlauf is an assistant professor of medicine; and Dr Scherl is a professor of clinical medicine in the Division of Gastroenterology and Hepatology at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York. |
| Abstrakt: |
The United States spends a greater share per gross domestic product on health care than any other developed country in the world. Cost-conscious, high-value care has an important role in the practice of medicine. Inflammatory bowel disease (IBD) affects 1.6 million people in the United States and is responsible for significant health care costs, with estimates as high as $31.6 billion annually, a large portion of which is attributable to the use of biologic therapies. As the number of therapeutic targets for IBD expands, gastroenterologists can anticipate the arrival of novel therapeutic agents on the market, and these may carry significant costs. Vedolizumab, a monoclonal antibody directed against the gut-selective integrin α4β7, is a novel biologic agent approved for the treatment of Crohn's disease and ulcerative colitis. Cost-effectiveness is an area of research that aims to assess the added value (in terms of both cost and utility) of diagnostic or therapeutic interventions. This article reviews the current literature evaluating the cost-effectiveness of vedolizumab for the treatment of IBD. |
